Biopharmaceutical companies increasingly rely on technology and service vendors to accelerate research and development and time to market, as well as optimize commercial success of therapies. These same companies are under pressure to increase efficiencies, maximize returns on approved therapies, and accelerate development time. Service and technology partners that help alleviate these pressures drive significant value in the marketplace and continue to attract attention from investors.
Access the Q4 sector update from our Healthcare & Life Sciences Group and our Technology Group for M&A trends in the outsourced pharma services and pharma tech space.
- Observations and key trends
- Perspectives on pharma services and tech
- Pharma services and tech market landscape
- What we’re reading
- Recent M&A activity
- Public company trended performance